Bone News and Research

RSS

Lawsuit against California Department of Health Care Services

AIDS Healthcare Foundation (AHF) has filed a federal lawsuit against David Maxwell-Jolly, Director of the California Department of Health Care Services (DHCS) seeking an injunction to prevent implementation of a new state law singling out nonprofit safety net providers—including AHF—forcing drastic Medi-Cal (Medicaid) reimbursements cuts for drugs purchased by AHF clinics and other safety net providers while favoring giant national for-profit pharmacy chains including Rite Aid, CVS, Walgreens and others.

10 Nov 2009

New school meal program can cause more harm than good, says nutrition experts

In attempts to improve the nutritional quality of school meals, there have been several strides forward - including the removal of soft drinks and other less nutritious menu options. However, some schools and activist groups are calling for a new change that many health professionals agree could cause more harm than good when it comes to children's health: removing chocolate milk from the lunch line.

10 Nov 2009

Study suggests a new improved treatment option for children with Hurler's syndrome

Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme - preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome.

10 Nov 2009

EpiCept announces third quarter 2009 financial results

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

10 Nov 2009

Harvest Technologies completes patient enrollment in its non-reconstructable Critical Limb Ischemia trial

Harvest Technologies Corp. announced today that the company sponsored 48-patient IDE clinical trial conducted at seven sites in the U.S. and one site in India using the company's Bone Marrow Aspiration Concentrate (BMAC) System to treat patients with non-reconstructable Critical Limb Ischemia (CLI) has completed enrollment. Mark D. Iafrati, M.D. Chief of Vascular Surgery at Tufts Medical Center in Boston, directed the study.

10 Nov 2009

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food & Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

10 Nov 2009

FDA grants marketing approval for Wright Medical Group's CONSERVE Plus Total Hip Resurfacing System

Wright Medical Group, Inc., a global orthopaedic medical device company, announced today that the United States Food and Drug Administration (FDA) has given approval to the Company to market its original CONSERVE® Plus Total Hip Resurfacing System. Now available in the United States, this innovative total surface arthroplasty system provides surgeons and their patients a bone-conserving alternative to traditional total hip replacement.

9 Nov 2009

Positive study data from Zosano Pharma's ZP-PTH transdermal patch for treating osteoporosis

Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, announced publication in the current issue of the Journal of Clinical Endocrinology and Metabolism of results from a positive phase 2 study of its rapid-delivery transdermal patch (ZP-PTH) for the treatment of postmenopausal osteoporosis.

9 Nov 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

GTx reports financial results for the third quarter of 2009

GTx, Inc. today reported financial results for the third quarter of 2009. The net loss for the third quarter and nine months ended September 30, 2009 was $12.8 million and $35.4 million, respectively, compared with a net loss of $11.9 million and $37.9 million for the same periods in 2008. At September 30, 2009 GTx had cash, cash equivalents and short-term investments of $55.5 million.

9 Nov 2009

BrainStorm Cell Therapeutics' approach for treating neurodegenerative diseases shown to be effective

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s therapeutic approach for treating neurodegenerative diseases was shown to be superior to other current potential stem cell treatments.

9 Nov 2009

$Connection between depression and loss of bone mass leads to osteoporosis and fractures$

Connection between depression and loss of bone mass leads to osteoporosis and fractures

Research carried out among thousands of people has shown a clear connection between depression and a loss of bone mass, leading to osteoporosis and fractures.

9 Nov 2009

Genetix Pharmaceuticals develops a gene therapy product to treat ALD

Genetix Pharmaceuticals, a leader in gene therapy of somatic stem cells, announced today the company’s clinical program to treat Adrenoleukodystrophy (ALD). The company is developing a gene therapy product in collaboration with Professor Patrick Aubourg and Doctor Nathalie Cartier of the National Institute of Health and Medical Research (INSERM).

7 Nov 2009

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma.

6 Nov 2009

Gene therapy saves two children with adrenoleukodystrophy

The ELA association and Zinedine Zidane, its emblematic ambassador, are proud to announce a world premiere: the results regaring the gene therapy in adrenoleukodystrophy conducted in France have just been published in the prestigious journal Science. Two children have been treated and their diseases have been halted. The children are doing well, which is unexpected for a disease destroying the brain in a few months. This discovery opens up treatment perspectives for numerous widespread diseases.

6 Nov 2009

Citracal Calcium plus Heart Health helps support bone and heart health in women

Bone strength and heart health are two of the most important health issues for women. One out of every two women will have an osteoporosis-related fracture in her lifetime and more than 50 million women have blood cholesterol levels high enough to pose a risk for heart disease. Now there is a new product available to help address both of these issues at the same time.

6 Nov 2009

Boosting NAD+ after spinal cord injury may prevent permanent nerve death

Substances naturally produced by the human body may one day help prevent paralysis following a spinal cord injury, according to researchers at Weill Cornell Medical College. A recent $2.5 million grant from the New York State Spinal Cord Injury Research Board will fund their research investigating this possibility.

6 Nov 2009

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.

6 Nov 2009

LDR reaches critical 24-month milestone in its Mobi-C cervical artificial disc study

LDR, a privately held company with innovative spinal implants for both non-fusion and fusion applications, reached the critical 24-month follow-up phase for the one-level IDE study on its second generation Mobi-C® cervical artificial disc. LDR is the first and currently the only company to have completed enrollment for a concurrent one-level and two-level cervical artificial disc replacement study. LDR completed 1-Level enrollment in October 2007 and 2-Level enrollment in March 2008.

6 Nov 2009

Prevalence of lactose intolerance may be far lower than previously estimated, says study

Prevalence of lactose intolerance may be far lower than previously estimated, according to a study in the latest issue of Nutrition Today. The study, which uses data from a national sample of three ethnic groups, reveals that the overall prevalence rate of self-reported lactose intolerance is 12 percent - with 7.72 percent of European Americans, 10.05 percent of Hispanic Americans and 19.5 percent of African Americans who consider themselves lactose intolerant.

6 Nov 2009

Bone News and Research

Lawsuit against California Department of Health Care Services

New school meal program can cause more harm than good, says nutrition experts

Study suggests a new improved treatment option for children with Hurler's syndrome

EpiCept announces third quarter 2009 financial results

Harvest Technologies completes patient enrollment in its non-reconstructable Critical Limb Ischemia trial

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

FDA grants marketing approval for Wright Medical Group's CONSERVE Plus Total Hip Resurfacing System

Positive study data from Zosano Pharma's ZP-PTH transdermal patch for treating osteoporosis

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

GTx reports financial results for the third quarter of 2009

BrainStorm Cell Therapeutics' approach for treating neurodegenerative diseases shown to be effective

Connection between depression and loss of bone mass leads to osteoporosis and fractures

Genetix Pharmaceuticals develops a gene therapy product to treat ALD

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

Gene therapy saves two children with adrenoleukodystrophy

Citracal Calcium plus Heart Health helps support bone and heart health in women

Boosting NAD+ after spinal cord injury may prevent permanent nerve death

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

LDR reaches critical 24-month milestone in its Mobi-C cervical artificial disc study

Prevalence of lactose intolerance may be far lower than previously estimated, says study

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News